This story originally ran on Sept. 9.
NanoInk this week said that its NanoBioDiscovery division has launched its contract research program.
The contract services will use NanoBioDiscovery's Dip Pen Nanolithography technology, which was developed by Chad Mirkin, a professor of chemistry at Northwestern University, and a founder of NanoInk.
The services being provided include custom assay development, analysis projects, protein profiling, and custom array printing, NanoBioDiscovery said in a statement. The division was formed in December as NanoInk shifted away from the semiconductor business, the original target market for its DPN technology, to the life science market. In March, a company official told ProteoMonitor that an instrument based on the technology, as well as its service business, would be launched during the third quarter [See PM 03/19/09].
The instrument has yet to launch, and a spokeswoman for NanoInk said this week the company had no update on when it will.
The DPN technology is a method of nanofabrication in which a sharp probe spots a biomolecule onto a surface, such as a glass slide. Data generated from an assay developed with the technology is similar to what can be achieved with an ELISA or other immunoassays, but because the DPN technology can precisely place the molecule on the surface, the donut-hole and coffee-ring effect seen with other spotting techniques can be avoided, leading to higher quality arrays, Bruce Dudzik, NanoInk's senior director for business development, said in March.
This week, NanoInk, based in Skokie, Ill., said that the DPN technology can deposit "highly reproducible, submicron protein features in one sub-array and [pattern] as many as 96 sub-arrays per slide."